Screening for sarcopenia: The SARC-F Questionnaire
The initial step in assessing for sarcopenia is a case-finding or screening process. Expert groups like EWGSOP2 and AWGS recommend using the SARC-F questionnaire. This five-item self-reported questionnaire helps identify individuals at risk in clinical settings.
Scores range from 0 to 10, with 4 or higher indicating high risk and the need for further assessment. The SARC-F covers:
- Strength (difficulty lifting/carrying 10 lbs)
- Assistance with walking
- Rising from a chair
- Climbing stairs
- Falls (frequency in the past year)
The EWGSOP2 diagnostic algorithm
The EWGSOP2 recommends a four-step F-A-C-S (Find-Assess-Confirm-Severity) approach for diagnosis.
Step 1: Find (Case-Finding)
Identify individuals potentially at risk using screening tools like SARC-F, SARC-CalF, or clinical suspicion.
Step 2: Assess (Muscle Strength)
Measure muscle strength if probable sarcopenia is suspected. Common methods include:
- Handgrip Strength Test: Measures maximum grip force with a dynamometer. Low strength is <27 kg for men and <16 kg for women.
- Five-Times-Sit-to-Stand (5xSTS) Test: Measures time to stand and sit five times without arm support. Over 15 seconds suggests low strength.
Step 3: Confirm (Muscle Quantity and Quality)
Confirm diagnosis by detecting low muscle mass or quality alongside low strength. Common methods include:
- Dual-energy X-ray Absorptiometry (DXA): Measures lean tissue mass, providing an Appendicular Skeletal Muscle Mass Index (ASMI).
- Bioelectrical Impedance Analysis (BIA): Estimates body composition using electrical currents. BIA is portable but can be affected by hydration.
Step 4: Severity (Physical Performance)
Classify severe sarcopenia based on poor physical performance if low strength and mass are confirmed. This is measured by:
- Gait Speed Test: Walking speed over 4 meters. ≤0.8 m/s is low.
- Short Physical Performance Battery (SPPB): Composite test of balance, gait speed, and 5xSTS. Score of 8 or less indicates poor performance.
- Timed Up-and-Go (TUG) Test: Time to rise, walk 3 meters, turn, return, and sit. ≥20 seconds indicates poor performance.
Comparison of sarcopenia assessment tools
| Assessment Tool | Type | What It Measures | Clinical Use | Pros | Cons |
|---|---|---|---|---|---|
| SARC-F Questionnaire | Self-report questionnaire | Symptoms associated with muscle function | Screening/Case-finding | Simple, quick, inexpensive, predictive of poor outcomes | Low sensitivity, doesn't directly measure muscle mass |
| Handgrip Dynamometry | Performance-based test | Maximum isometric muscle strength | Diagnosing low muscle strength | Quick, inexpensive, well-validated as an indicator of overall strength | May not fully reflect lower body strength |
| DXA Scan | Imaging | Appendicular skeletal muscle mass (ASMI) | Confirming low muscle quantity | Accurate, low-radiation, provides body composition breakdown | Less accessible in routine clinical practice, moderate cost |
| BIA | Bioelectrical measurement | Total body water, used to estimate muscle mass | Confirming low muscle quantity | Portable, inexpensive, quick, no radiation exposure | Results can be affected by hydration status and edema |
| Gait Speed Test | Performance-based test | Walking speed over a short distance (e.g., 4m) | Evaluating severity of sarcopenia | Quick, reliable, widely used, predictive of adverse outcomes | Can be influenced by practice and technician skill |
| SPPB | Composite performance-based battery | Balance, gait speed, and chair stands | Evaluating severity of sarcopenia | Comprehensive assessment of lower body function, predictive of disability | More time-consuming than single tests |
The Mini Sarcopenia Risk Assessment (MSRA) questionnaire
The Mini Sarcopenia Risk Assessment (MSRA) is another screening tool with seven items covering general and dietary risk factors for muscle loss, including age, activity levels, hospitalizations, weight loss, meals per day, and protein/dairy intake. The MSRA includes nutritional aspects, unlike SARC-F. A score of 30 or less on the original version indicates risk. The shorter MSRA-5 also shows promise and can be combined with calf circumference for improved accuracy.
Biomarkers and other advanced methods
While not standard clinical practice, research is exploring biomarkers and advanced imaging. Examples include:
- Biomarkers: Investigating markers like the creatinine to cystatin C ratio and inflammatory markers (IL-6, TNF-α).
- Advanced Imaging: CT and MRI provide detailed muscle measurements but are costly and often used in research.
Conclusion
Sarcopenia assessment is a multi-tiered process, not a single form. It starts with screening tools like SARC-F or MSRA to find at-risk individuals. A diagnosis then follows a clinical pathway, such as the EWGSOP2's F-A-C-S approach, using objective measurements of muscle strength, mass, and physical performance. This systematic method ensures comprehensive evaluation for timely intervention.
BMC Geriatrics is a trusted source for research on geriatric health, including sarcopenia assessment and diagnosis.
